The Research Pharmacy Core (RP) is essential to the translational work of MSKCC. The Core supports the ability of MSKCC to advance its scientific discoveries from laboratory-based investigations to clinical-based Proof-of-Concept testing. The RP has three principal components: 1) The Pharmaceutical Product Facility (PPF) for drug formulation/stability and compatibility issues; 2) The Clinical Grade Production (CGP) Facility for bulk product purification and vialing; and 3) the Pharmacy Investigational Drug Service (PIDS) which supports the preparation and packaging of Investigational drugs for preclinical and clinical use. The RP staff provide consultation, bulk product analysis and purification, formulation, vialing, labeling, stability/sterility testing, and dispensing. The RP works hand-in-hand with the Investigational Products Core to prepare the Chemistry, Manufacturing, and Control Section for each of MSKCC's IND's. Through the RP, MSKCC can advance internal ideas into early human testing. Owing to the infrastructure of the RP, MSKCC has been able to bring multiple distinct types of pharmacologic agents into early clinical trials. These include traditional small molecules, radiopharmaceuticals, and vaccines. The services provided by the core have supported the research of 24 investigators from 5 Programs and 49 IRB protocols in the last year. Since the last review, the work of the Core has contributed to 25 publications from 5 Programs. For example, the therapeutic antibody 3F8 is purified, manufactured, and vialed exclusively at MSKCC and forms the backbone of the research program in neuroblastoma. It has now been validated as an effective treatment for children with neuroblastoma. The large and complex vaccine program, integrating both carbohydrate and peptide vaccines on complex KLH backbone or in mixtures with novel adjuvants is also dependent on the services of the tripartite RP to support the clinical testing of vaccines against cancers Including serous ovarian cancer, leukemia, mesothelioma, and sarcoma.

Public Health Relevance

The Research Pharmacy provides services and expertise associated with the preparation, analysis and dispersion of investigational drugs. The Core is essential to the translational work at the Center and serves as a key conduit to deliver research discoveries from Center investigators to clinicians for human proof-of-concept testing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-50
Application #
8986766
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
50
Fiscal Year
2016
Total Cost
$206,350
Indirect Cost
$90,227
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Creasy, John M; Sadot, Eran; Koerkamp, Bas Groot et al. (2018) Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 163:1238-1244
Cracchiolo, Jennifer R; Patel, Krupa; Migliacci, Jocelyn C et al. (2018) Factors associated with a primary surgical approach for sinonasal squamous cell carcinoma. J Surg Oncol 117:756-764
Simon, Claire S; Hadjantonakis, Anna-Katerina; Schröter, Christian (2018) Making lineage decisions with biological noise: Lessons from the early mouse embryo. Wiley Interdiscip Rev Dev Biol 7:e319
Ghasemiesfe, Mehrnaz; Ravi, Divya; Vali, Marzieh et al. (2018) Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Ann Intern Med 169:106-115
Benedict, Catherine; DuHamel, Katherine; Nelson, Christian J (2018) Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors. Psychooncology 27:691-694
Gao, Song; Stein, Seth; Petre, Elena N et al. (2018) Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. Cardiovasc Intervent Radiol 41:253-259
Perrier, Nancy D; Brierley, James D; Tuttle, R Michael (2018) Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 68:55-63
Jee, David; Yang, Jr-Shiuan; Park, Sun-Mi et al. (2018) Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals. Mol Cell 69:265-278.e6
Mirpuri, Sheena; Gill, Pavan; Ocampo, Alex et al. (2018) Discrimination and Health Among Taxi Drivers in New York and Toronto. J Community Health 43:667-672
Jones, Christopher W; Misemer, Benjamin S; Platts-Mills, Timothy F et al. (2018) Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study. BMJ Open 8:e019831

Showing the most recent 10 out of 8799 publications